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Although reports on pleurodesis date back to the beginning of the 20th century, the search for the ideal sclerosing agent is
ongoing. Several agents have been studied and used, but talc continues to be the most popular. However, potentially harmful
systemic side effects have been associated with talc pleurodesis. In this article we discuss the likely mechanisms of pleural
inflammation and pleurodesis with emphasis on the systemic response due to the instillation of talc into the pleural space.
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Pleural effusion is a frequent manifestation, in part be-
cause of the increase in the incidence of cancer and, mainly,
because of the survival of patients with malignant neo-
plasms.1,2 Since the presence of pleural effusion is indica-
tive of disseminated disease and limited survival, the main
objective of treatment is to offer a better quality of life to
the patients, relieving symptoms basically characterized by
dyspnea and pain.2 In addition, since systemic treatment
frequently does not control the disease, the local approach
to pleural effusion (in addition to drainage of the cavity
for immediate improvement of manifestations) is the con-
trol of recurrence by sclerosis and symphysis of the pleu-
ral membranes, a process called pleurodesis.
The first reports on pleurodesis date back to the begin-
ning of the 20th century,3 and although more than 100 years
have passed since then and different agents have been em-
ployed, the search for the ideal sclerosing agent continues.4
Some antibiotics have demonstrated a sclerosing effect (tet-
racycline),5 whereas no marked efficacy has been observed
for others (macrolides and quinolones).6 Similarly, antine-
oplastic agents (bleomycin),7 immunostimulants (Coryne-
bacterium parvum and OK-432),8,9 chemical irritants (talc
and silver nitrate),10,11 and more recently, biological media-
tors of inflammation (transforming growth factor–beta
(TGF-β) and interferon)12,13 have been effective in the pro-
duction of pleurodesis. The use of povidone-iodine,14 au-
tologous blood,15 and polidocanol16 has also been reported
in some studies.
Among the different substances proposed for the induc-
tion of pleurodesis, talc is the agent most used in clinical
practice. Talc, a magnesium silicate hydroxide
[Mg3Si4O10(OH)2], has become popular because of its wide
availability and high therapeutic success rate, which is close
to 90%.17 Talc is applied to the pleural space by injection
in saline solution (slurry) or by dusting during pleuroscopy
(poudrage).18
However, despite its widespread use, the instillation of
talc is not devoid of side effects, including chest pain, fe-
ver, arrhythmias, and dyspnea.18-20 Dyspnea is the most
feared side effect because in more severe cases, this con-
dition may result in acute respiratory distress syndrome,
with an incidence reaching 9% and a potentially fatal out-
come.20,21
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Systemic effects of talc
The mechanisms underlying the systemic effects of talc,
especially respiratory distress syndrome, are still unknown.
The possible and most likely causes include the migration
of talc particles from the pleural cavity to the systemic cir-
culation, changes provoked by the different talc components
(including the presence of contaminating agents), establish-
ment of an intracavity inflammatory process (source of in-
flammatory mediators), and surgical procedures performed
(biopsies) that provide an access route that facilitates the sys-
temic absorption of talc and inflammatory mediators.22-25
Migration of talc from the pleura to the systemic
circulation
Considering the extensive surface of the human pleu-
ral cavity (≅ 1 to 2 m2),26 as well as the efficient drainage
system of the cavity by pleural lymphatic vessels, the hy-
pothesis that absorption of talc particles plays a role in the
genesis of systemic effects should be taken into account.23
Studies have shown heterogeneity in particle size among
talc preparations used for pleurodesis.27 Accordingly, one
may speculate that smaller particles are more likely to be
absorbed by the systemic circulation, causing the adverse
effects described.24,25,27
In 1999, Werebe et al,28 studying the dissemination of
talc (particles measuring 5.7 to 70 µm) in rats, observed
the presence of talc in bronchoalveolar lavage fluid and dif-
ferent organs (brain, liver, spleen, heart, and contralateral
lung). Subsequently, in 2002, Ferrer et al27 compared the
induction of pleurodesis in rabbits using talc commonly
employed in pleurodesis (particles of ≅ 8.3 µm) and talc
with particles of a larger size (12 µm). The authors observed
talc particles in the mediastinum pericardium and liver.
Pleural inflammation and talc deposition were greater in
the group receiving smaller particles. In the same year,
Fraticelli et al,29 using talc with larger particles (mean of
33 µm), identified the presence of a few talc particles in
the brain, liver, and spleen, and a cross-contamination of
these tissues during storage and processing of the samples
was not excluded as a possible cause of the presence of
talc in these tissues.
Our group also investigated the extrapleural dissemina-
tion of talc particles in rabbits, comparing small talc (mean
particle size: 4.2 µm, with 50% of particles < 5 µm) and
mixed talc (mean particle size: 25.4 µm, with 90% of par-
ticles > 10 µm) (Figure 1). We found talc deposition in the
contralateral lung, liver, kidneys, and spleen, with a larger
amount being observed in animals injected with talc com-
prised of small particles.30,31
Talc composition and contaminants
Another possible cause of systemic alterations is dif-
ferences in talc composition, which varies in the amount
of calcium, aluminum, and iron according to its origin.
Similarly, mineral contaminants may produce local and sys-
temic effects, with emphasis on the presence of magnesite,
dolomite, caolinite, calcite, chlorite, serpentine, and
quartz.32
Intracavity inflammatory process
Another possible cause of systemic side effects is the
intense inflammatory process that is observed in the pleu-
ral space after talc application, producing cytokines, ad-
hesion molecules, and other mediators of inflammation.24,33
The presence of local and systemic inflammatory al-
terations has been demonstrated in humans undergoing talc
pleurodesis. In these patients, impaired DTPA clearance and
changes in the alveolar-arterial oxygen gradient and serum
Figure 1 - Talc samples used. Left, talc containing small particles (< 5 µm). Right, mixed talc (90% of particles > 10 µm). Magnification: x400.
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C-reactive protein levels were observed.34,35 Additionally,
chest computed tomography and positron emission tomog-
raphy demonstrated alterations characteristic of acute pleu-
ral inflammation related to the loss of the integrity of the
pleural barrier, consequently facilitating the absorption of
talc particles and inflammatory mediators.36
Inflammatory response
The chain of events that leads to the occurrence of lo-
cal and systemic effects is triggered by the inflammatory
response to talc components or contaminants or even to in-
flammatory mediators produced as a result of intrapleural
talc administration.37 Thus, the understanding of this re-
sponse is of great importance, taking into account cytologi-
cal (particularly the acute response mediated by leukocytes
and neutrophils), biochemical, and cytokine parameters.
Analysis of the the response of leukocytes, and particularly
that of neutrophils, is justified by the fact that a cellular
response predominates in the pleural cavity, with lactate
dehydrogenase being the main enzyme reflecting manifes-
tations of an acute exudate.37
Main components
The inflammatory chain involves the production and
release of modulatory substances that act on the produc-
ing cells themselves. In this respect, the key function of
mesothelial cells was formerly believed to be the protec-
tion against aggression, with these cells being regarded as
lining cells functioning as structural barriers. However, it
is now known that mesothelial cells are not simple passive
participants but are in fact responsible for the orchestra-
tion of the entire intrapleural inflammatory response, act-
ing on the regulation of the production of diverse media-
tors such as interleukin 8 (IL-8), vascular endothelial
growth factor (VEGF), and TGF-β.37
The predominant characteristics of IL-8, a cytokine in-
volved in the acute inflammatory response, are neutrophil
chemotaxis and marked resistance to proteolysis, with this
cytokine also being associated with leukocyte activity dur-
ing inflammatory processes in the pleural cavity.38
Vascular endothelial growth factor has 2 main proper-
ties, ie, the capacity to increase capillary permeability and
a marked angiogenic and lymphogenic potential. It is
present in inflammation areas and is found to be increased
in exudative effusions, with this factor being implicated in
the genesis and maintenance of pleural effusion.37
Tumor growth factor–beta presents profibrotic and
immunomodulatory properties. Animal studies have dem-
onstrated that TGF-β stimulates collagen synthesis and in-
duces pleurodesis without causing acute inflammatory ef-
fects. Injection of TGF-β into the pleural space of rabbits
increases VEGF levels in pleural fluid, and in vitro stud-
ies have shown that TGF-β stimulates the production of
VEGF by mesothelial cells.38
Types of talc and inflammation
One of the main hypotheses raised to explain the sys-
temic effects observed in pleurodesis is the migration of
talc particles. Accordingly, smaller particles are believed
to cause a more intense acute systemic inflammatory re-
sponse than talc with particles of larger sizes. However, in
fact, irrespective of particle size, talc injected into the pleu-
ral cavity produces an acute systemic response, with the
presence of talc particles being rapidly detected in various
organs (24 hours after intrapleural injection). Nevertheless,
serum and pleural fluid inflammatory parameters indicate
that small-particle talc (< 5 µm) produces a more prolonged
and more intense systemic and pleural response.28,39 There-
fore, talc administration leads to an increase in the serum
levels of IL-8, VEGF, and TGF-β and in pleural levels of
IL-8 and VEGF, irrespective of particle size, with these lev-
els being more elevated when small-particle talc is in-
jected.30 Nasreen et al40 demonstrated that mesothelial cells
stimulated by talc produce adhesion molecules and
cytokines, emphasizing the importance of talc for the
mechanism of pleural inflammation in pleurodesis.
In clinical studies, Maskell et al35 demonstrated that talc
of varying particle size (50% of particles < 10 µm) exerts
more pronounced effects on the lung clearance of DTPA
and serum IL-8 and C-reactive protein levels than tetracy-
cline, in addition to causing more lung and systemic al-
terations. Another study of the same group compared
pleurodesis obtained with mixed talc and graded talc in
which 50% of the particles were smaller than 20 µm, with
most particles smaller than 10 µm being removed for ho-
mogenization of the sample. Measuring the alveolar-arte-
rial oxygen gradient and C-reactive protein levels, the au-
thors demonstrated more systemic and lung inflammation,
accompanied by worsened gas exchange, in pleurodesis in-
duced with small-particle talc. The final outcome of
pleurodesis was the same after 3 months (85% success in
both groups).34 Recently, Froudarakis et al41 evaluated the
role of talc in the systemic inflammatory response com-
paring diagnostic thoracoscopy and thorascopic talc
poudrage. Talc was found to actively participate in the sys-
temic reactional process, causing an increase in leukocyte
count and in the percentage of neutrophils, associated with
fever. In addition, C-reactive protein levels were signifi-
cantly higher in the group submitted to talc poudrage.
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The above mentioned facts are important, since no
standardization exists for talc production, and there is a
wide variation in the composition and particle size among
the various talc preparations used worldwide. This fact has
been demonstrated by Ferrer et al,27 who attributed side ef-
fects to the smaller size of the particles in the talc used in
different services. A similar efficacy of pleurodesis was re-
ported by the same group when comparing 200 mg/kg of
talc used in clinical practice (particle diameter: 8.36 ± 0.20
µm) and talc with particles of larger size (diameter: 12 ±
0.25 µm), but pleural inflammation was greater when the
injected talc contained smaller particles.27,32 Montes et al,25
comparing 2 different talc doses (50 or 200 mg/kg), noted
a more intense systemic response with the higher dose, in-
cluding an increase in the number of lymphocytes,
monocytes, neutrophils, and platelets.
The more intense pleural inflammation and the more
prolonged systemic response observed after the adminis-
tration of small talc (50% of particles < 5 µm), leads to
different speculations regarding the possible mechanisms
of inflammation. We believe that the greater pleural inflam-
matory response observed after the administration of talc
containing small particles is a consequence of the larger
number of particles per area in the cavity. Furthermore,
smaller particles probably are more easily engulfed by in-
flammatory cells present in the pleural space, in the ab-
sence of intense cellular necrosis, a fact that might explain
the observation of a larger number of intact neutrophils,
the lower lactate dehydrogenase levels, and the more
marked release of inflammatory mediators (cytokines). On
the other hand, mixed talc (90% of particles > 10 µm)
presents a rough spike-like shape and may cause more in-
tense damage to mesothelial cells by a direct mechanical
action, resulting in greater cellular necrosis accompanied
by increased lactate dehydrogenase levels.30
Systemic inflammatory response
Regardless of the type of talc used, the systemic re-
sponse observed in pleurodesis is believed to be the result
of the passage of inflammatory mediators or talc particles
from the pleura to the blood circulation. This passage may
occur through the lymphatic route23, 26, 27 (drainage into the
venous system and deposition in the lungs) or by direct pas-
sage into the bloodstream due to the loss of integrity of
the alveolar-capillary barrier secondary to the intense in-
flammation in the pleural cavity.10
The first mechanism, ie, spilling of inflammatory me-
diators, is supported by the view that in the pleural cavity,
IL-8 levels increase early and decline over time, whereas
the opposite is observed in blood.10 In parallel, VEGF lev-
els tend to increase progressively in both pleural fluid and
blood, reflecting an increase in capillary permeability,
which contributes to both the production of pleural fluid
and the passage of smaller molecules from the cavity to
the blood circulation. We observed that only TGF-β levels
after instillation of small talc (50% of particles < 10 µm)
and VEGF levels after administration of mixed talc (90%
of particles > 10 µm) presented a strong pleura-serum cor-
relation (Figure 2), suggesting a possible communication
between the 2 compartments.30,41-43 Despite this observation,
these data alone do not permit the inference that this is the
only mechanism involved in the systemic response observed
in talc pleurodesis.
Comparison of these parameters shows a positive cor-
relation between VEGF and TGF-β levels in pleural fluid,
demonstrating a possible proinflammatory effect of TGF-
β. This possibility has been suggested in a previous study
in which TGF-β was found to stimulate the production of
VEGF by mesothelial cells, a finding explaining in part the
increased vascular permeability observed in inflammation
Figure 2 - Comparison of tumor growth factor–beta (TGF-β) and vascular endothelial growth factor (VEGF) levels in pleural fluid and blood of rabbits
submitted to intrapleural injection of small-particle talc and mixed talc, respectively.
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after pleurodesis.43 However, we observed higher pleural
VEGF levels after the administration of small talc (< 5 µm)
compared with mixed talc (90% of particles > 10 µm),
whereas TGF-β levels were higher in animals injected with
mixed talc, suggesting a possible overlapping of distinct
inflammatory mechanisms.30,44
In addition to inflammatory mediators, an acute serum
increase of leukocytes and neutrophils is also observed in
both talc groups, coinciding with the acute pleural inflam-
matory response. However, no conclusion can be drawn
about whether the systemic cellular response is the result
of the flow of cells from the pleural cavity to the blood
circulation or whether it is a direct response to the pres-
ence of talc particles in the organs.30,31 Therefore, future
studies correlating the cellular response with the number
of particles deposited in tissues will contribute to clarify-
ing this question.
Another mechanism that might explain the systemic in-
flammatory response is the direct passage of talc particles
from the pleural space into the blood circulation. The pres-
ence of talc particles in intrathoracic and extrathoracic tis-
sues has been the subject of many studies. Ferrer et al27,32
suggested that small particles are more easily absorbed by
lymphatic stomata (which, in humans, measure about 6.2
µm in diameter26) and are carried by lymphatic vessels, trig-
gering an inflammatory response that provokes acute lung
injury in the form of adult respiratory distress syndrome.
This assumption is justified by the fact that all series in
which cases of respiratory insufficiency were reported were
from North America (a country presenting the smallest par-
ticles among those studied). Curiously, no case of adult res-
piratory distress syndrome was reported in 2 large series
(one European and another Israeli series).24,32
Our studies agree with the previously described find-
ings and emphasize the observation that the particles
present in the organs studied are all smaller than 5 µm, sug-
gesting that the systemic effects observed can be explained
by the presence of small particles. The same mechanism
may explain the systemic effects observed after the admin-
istration of mixed talc, since about 10% of the particles in
this type of talc are smaller than 10 µm. However, if we
assume that the probable mechanism of talc particle mi-
gration from the pleural cavity to the systemic circulation
involves lymphatic absorption, it would be difficult to ex-
plain the presence of talc particles in the liver, spleen, and
kidney (Figure 3), because these particles enter the systemic
venous circulation and return to the lung where they are
retained. Therefore, we believe that lymphatic absorption
is not the only mechanism involved, and we speculate that
the intense inflammation caused by talc promotes the loss
of integrity of the capillary barrier, permitting the free flow
between the 2 compartments.
These considerations permit us to infer that the mecha-
nism underlying the systemic inflammatory response ob-
Figure 3 - Photomicrographs of the left (A) and right lung (B), spleen (C), liver (D), and kidney (E) of rabbits submitted to th intrapleural instillation of
small-particle talc (< 5 µm) (upper panel) and mixed talc (90% of particles > 10 µm) (lower panel) obtained after 24 hours (hematoxylin and eosin, polarized
light, magnification: x200). Note the scattered birefringent talc particles observed in both images.
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served in talc pleurodesis remains to be established. How-
ever, it seems reasonable to assume that particle size in-
fluences the inflammatory response and, possibly, the side
effects observed in clinical practice, since talc migration
to other organs has been demonstrated.
We conclude that talc-containing particles of small size
cause more marked pleural inflammation and a greater sys-
temic inflammatory response, accompanied by extrapleural
talc deposition in various organs. The mechanisms under-
lying these phenomena are still not completely understood,
and further studies on this subject are necessary, especially
those investigating the mechanisms of talc particle migra-
tion.
AUTHORS’ NOTE
The talc used by the Discipline of Pneumology, Uni-
versity of São Paulo Medical School (HC-FMUSP), com-
prises a wide variation in particle size, with about 10% con-
sisting of particles smaller than 10 µm. Considering that
about 5 g of talc is instilled during pleurodesis induction,
about 500 mg of this agent comprises particles smaller than
10 µm. Thus, for a pleural surface of about 2000 cm2, 500
mg of small-particle talc corresponds to 4 mg/cm2 (4000
µg/cm2), a dose considered to be extremely high and po-
tentially toxic to the mesothelium. We demonstrated in cell
culture experiments that doses higher than 48 µg/cm2 pro-
voke mesothelial cell necrosis.44,45
RESUMO
Genofre EH, Marchi E, Vargas FS. Repercussões clínicas
e inflamatórias de pleurodese induzida pela administração
intrapleural de talco. Clinics. 2007; 62(5):627-34.
Apesar dos relatos sobre pleurodese remontarem ao início
do século XX, ainda hoje se busca o agente esclerosante
ideal. Diversos agentes foram estudados e utilizados, mas
o talco é considerado o mais popular. No entanto, efeitos
sistêmicos potencialmente tóxicos tem sido associados à
pleurodese pelo talco. Neste artigo discutimos os prováveis
mecanismos de inflamação pleural e pleurodese, com
ênfase na resposta sistêmica produzida pela instilação in-
trapleural de talco
UNITERMOS: Talco. Pleurodese. Inflamação. Pleura.
Efusão Pleural.
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